Appeals Court Rules Generic Label Would Direct Docs to Infringe Use Patent

Drug Industry Daily
The Federal Circuit upheld two Sanofi patents for its antiarrhythmic drug Multaq (dronedarone) — agreeing with Sanofi’s argument that the drug’s label, which is required to be similar for any generic versions, would ultimately direct physicians to violate the company’s patent on using Multaq to prevent abnormal heart rhythms.

To View This Article:


Subscribe To Drug Industry Daily